What it's for (Indications)
- Formoterol is a long-acting beta2-adrenergic agonist (LABA) indicated for the long-term maintenance treatment of asthma in patients 5 years of age and older, and for the long-term maintenance treatment of bronchoconstriction associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, in adults.
- It is crucial to emphasize that formoterol, when used for asthma, must always be co-administered with an inhaled corticosteroid (ICS) due to the increased risk of serious asthma-related events associated with LABA monotherapy in asthma.
- For COPD, formoterol may be used as monotherapy.
- It is not indicated for the relief of acute bronchospasm or for patients experiencing rapidly deteriorating asthma or severe exacerbations, as it is a maintenance therapy, not a rescue medication.
- Its use is focused on preventing symptoms over time rather than providing immediate relief during an acute attack.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of formoterol varies depending on the specific product formulation (e.g., dry powder inhaler, metered-dose inhaler, nebulizer solution) and the patient's condition (asthma or COPD). For dry powder inhaler formulations of formoterol fumarate, typical maintenance dosing for both asthma and COPD is 12 micrograms (mcg) administered twice daily, approximately every 12 hours. In combination products with an inhaled corticosteroid, the formoterol component is often 4.5 mcg or 6 mcg, also administered twice daily. The maximum recommended dose for monotherapy formoterol is generally 24 mcg per day. Patients should always follow the specific instructions provided by their healthcare professional and adhere to the dosage regimen detailed in the product information for their prescribed medication. Formoterol should not be used more often than recommended or at higher doses than prescribed due to the increased risk of adverse effects. It is vital to use the correct inhalation technique as instructed by a healthcare provider to ensure optimal drug delivery. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects associated with formoterol include headache, tremor, palpitations, dizziness, nausea, dry mouth, muscle cramps, and cough.
- Less common but potentially serious side effects include paradoxical bronchospasm, which is a life-threatening acute worsening of breathing that requires immediate discontinuation of the drug and alternative therapy.
- Cardiovascular effects such as tachycardia, arrhythmias (including atrial fibrillation and supraventricular tachycardia), QT interval prolongation, and hypertension may occur, particularly in susceptible individuals or with excessive dosing.
- Metabolic effects like hypokalemia (decreased potassium levels) and hyperglycemia (increased blood sugar levels) have also been observed.
- Hypersensitivity reactions, though rare, can manifest as rash, urticaria, angioedema, or bronchospasm.
- Patients should be advised to report any persistent or worsening symptoms to their healthcare provider promptly, especially if they experience chest pain, rapid heart rate, or severe dizziness.
Serious Warnings
- Black Box Warning: **WARNING: ASTHMA-RELATED DEATHS** Long-acting beta2-adrenergic agonists (LABAs) such as formoterol, when used as monotherapy for asthma, increase the risk of asthma-related death. Data from a large, randomized, placebo-controlled clinical trial demonstrated an increased risk of asthma-related deaths in patients receiving salmeterol, another LABA, compared to placebo-treated patients. This finding is considered a class effect of LABAs. Therefore, formoterol should only be used in patients with asthma as concomitant therapy with an inhaled corticosteroid (ICS). Formoterol is not indicated for the relief of acute bronchospasm. It should not be initiated in patients experiencing rapidly deteriorating asthma or life-threatening episodes of asthma or COPD. The safety and efficacy of formoterol as monotherapy in asthma have not been established. It is imperative that healthcare providers ensure patients with asthma are concurrently prescribed and appropriately using an ICS to mitigate this serious risk. Patients should be explicitly educated about this risk and the necessity of combination therapy for asthma management.
- Formoterol, as a long-acting beta2-adrenergic agonist (LABA), is associated with several important warnings.
- It is not intended to relieve acute bronchospasm; a short-acting beta2-agonist (SABA) should be used for acute symptoms.
- Therapy should not be initiated in patients experiencing rapidly deteriorating asthma or severe exacerbations.
- Exceeding the recommended dose or frequency can lead to clinically significant cardiovascular effects, including increased heart rate, blood pressure, and potential arrhythmias.
- Patients with pre-existing cardiovascular disorders (e.
- g.
- , coronary artery disease, cardiac arrhythmias), convulsive disorders, thyrotoxicosis, or diabetes mellitus should use formoterol with caution and under close medical supervision due to the potential for exacerbation of these conditions.
- The drug can cause hypokalemia and hyperglycemia, requiring monitoring in susceptible populations.
- Discontinuation should not be abrupt, especially if combined with an ICS, to avoid potential withdrawal symptoms or asthma exacerbations.
- Patients should be thoroughly educated on proper use and monitoring.
How it Works (Mechanism of Action)
Formoterol is a highly selective, long-acting beta2-adrenergic receptor agonist. Upon inhalation, it directly stimulates beta2-adrenergic receptors located primarily on the smooth muscle cells of the bronchial airways. This stimulation leads to the activation of adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Increased intracellular levels of cAMP result in the relaxation of bronchial smooth muscle, leading to bronchodilation. Formoterol exhibits a rapid onset of action (within minutes) and a prolonged duration of effect (up to 12 hours) due to its high lipophilicity, which allows it to partition into the lipid bilayer of the cell membrane, creating a drug reservoir that sustains receptor binding and activation over an extended period. This mechanism helps in maintaining open airways, thereby improving airflow and reducing symptoms of bronchoconstriction in conditions like asthma and COPD, without affecting cardiac beta1 receptors significantly at therapeutic doses.
Commercial Brands (Alternatives)
No other brands found for this formula.